Table S2. Parameters used in Eq. (2) for the simplified Oct4-Nanog model. (DOCX 42Â kb
Excel tables for genes significantly upregulated in MESP1+ cells compared with undifferentiated hESC...
Supplemental Methods and Results. A supplementary Table (Table S1) summarizing the pertinent literat...
Table S13. List of signaling pathways used in Additional file 1: Figure S7a. (XLSX 20 kb
Figure S3. Parameter sensitivity analysis for the model. Illustration of the relative changes of the...
Figure S2. The simplified two-dimensional Oct4-Nanog model on the phase plate and the distribution o...
Figure S6. Three different strategies of reprogramming demonstrate additional Nanog activation is ne...
Figure S5. The MAP of the reprogramming process in the WT model. The MAP (white curve) starting from...
Immunopositivity for stem cell reprogramming factors in malignant and benign vascular tumors. Table ...
Additional file 3: Supplementary Fig. 1. Reprograming efficiency and doubling time of iPSCs, related...
Generation and characterization of induced pluripotent stem cell (iPSC) clones derived from wildtype...
Optimal small-molecule combination screening. (A) Selection of small-molecule combinations. (B) Conc...
Figure S4. Gene expression centroids from the adult FBS erythropoiesis data as depicted in Fig. 1B....
In vitro differentiation analysis and karyotyping of LiPSC. (A) Representative karyotype of the esta...
Figure S2. Differentiated PB iPSC clones did not express pluripotency markers OCT4, NANOG, TRA-1-60,...
Figure S1. Targeted deletion of MEIS2 in human hESCs. (A) Surveyor assay of sgMESI2-E3G3-mediated cl...
Excel tables for genes significantly upregulated in MESP1+ cells compared with undifferentiated hESC...
Supplemental Methods and Results. A supplementary Table (Table S1) summarizing the pertinent literat...
Table S13. List of signaling pathways used in Additional file 1: Figure S7a. (XLSX 20 kb
Figure S3. Parameter sensitivity analysis for the model. Illustration of the relative changes of the...
Figure S2. The simplified two-dimensional Oct4-Nanog model on the phase plate and the distribution o...
Figure S6. Three different strategies of reprogramming demonstrate additional Nanog activation is ne...
Figure S5. The MAP of the reprogramming process in the WT model. The MAP (white curve) starting from...
Immunopositivity for stem cell reprogramming factors in malignant and benign vascular tumors. Table ...
Additional file 3: Supplementary Fig. 1. Reprograming efficiency and doubling time of iPSCs, related...
Generation and characterization of induced pluripotent stem cell (iPSC) clones derived from wildtype...
Optimal small-molecule combination screening. (A) Selection of small-molecule combinations. (B) Conc...
Figure S4. Gene expression centroids from the adult FBS erythropoiesis data as depicted in Fig. 1B....
In vitro differentiation analysis and karyotyping of LiPSC. (A) Representative karyotype of the esta...
Figure S2. Differentiated PB iPSC clones did not express pluripotency markers OCT4, NANOG, TRA-1-60,...
Figure S1. Targeted deletion of MEIS2 in human hESCs. (A) Surveyor assay of sgMESI2-E3G3-mediated cl...
Excel tables for genes significantly upregulated in MESP1+ cells compared with undifferentiated hESC...
Supplemental Methods and Results. A supplementary Table (Table S1) summarizing the pertinent literat...
Table S13. List of signaling pathways used in Additional file 1: Figure S7a. (XLSX 20 kb
DOI
Add to ORKG